Maxim Group analyst Jason McCarthy maintained a Hold rating on Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) today. The company’s shares opened today at $1.57, close to its 52-week low of $1.45.
McCarthy noted:
“Sonoma announced that it has licensed its antimicrobial hypochlorous solution, to be branded as Pharma, S.L. (private) for use in blepharitis. Brill Pharma is based in Barcelona.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 19.2% and a 55.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sonoma Pharmaceuticals Inc with a $3 average price target.
See today’s analyst top recommended stocks >>
Based on Sonoma Pharmaceuticals Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.46 million. In comparison, last year the company had a GAAP net loss of $3.51 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. It offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses.
